USIM3
vs
B
BOVESPA
USIM3
Over the past 12 months, USIM3 has underperformed BOVESPA, delivering a return of +7% compared to the BOVESPA's +48% growth.
Stocks Performance
USIM3 vs BOVESPA
Performance Gap
USIM3 vs BOVESPA
Performance By Year
USIM3 vs BOVESPA
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Usinas Siderurgicas de Minas Gerais SA USIMINAS
Glance View
Usinas Siderúrgicas de Minas Gerais SA, commonly known as USIMINAS, stands as one of Brazil's most significant steel manufacturers, nestled in a region rich in the very resources that feed its voracious industrial appetite. With roots stretching back to the mid-20th century, USIMINAS was born out of a strategic need to boost the country's industrial capabilities. The lush hills of Minas Gerais provide an ample supply of iron ore, which acts as the lifeblood for the firm’s numerous blast furnaces. These towering giants turn raw materials into a wide array of steel products that are further processed into high-quality flat steel sheets. Through comprehensive mining operations and efficient steel production techniques, USIMINAS ensures a continuous supply of material to satiate both local and international demand. Operational prowess aside, USIMINAS crafts its revenue streams largely by serving sectors that form the backbone of modern economies: automotive, construction, and general manufacturing. By supplying the steel that becomes the frame of a car, the structure of a skyscraper, or the underpinnings of machinery, the company embeds itself deeply into the infrastructure of growth across South America and beyond. Despite the cyclical nature of the steel industry, USIMINAS has maintained resilience by innovating its production methods, tapping into eco-friendly practices, and shifting gears to meet evolving market demands. Through strategic partnerships and an adaptive business model, USIMINAS not only sustains its profitability but also fortifies its position as a stalwart of industrial progress in Brazil.
